The inaugural screening is the first in a series of proactive efforts dedicated to identifying chronic kidney disease early and managing its risk factors comprehensively.
Dr Zanariah Hussein highlights SGLT2-i, a new glucose-lowering drug that helps prevent cardiovascular and renal death, but usage is low due to MOH’s limited budget.